CARNABIOSCIENCES-C1763102
Phase I
OPEN TO ACCRUAL
A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non Hodgkin Lymphoma
DAIICHI-SANKYO-DS3201-343
Phase I
OPEN TO ACCRUAL
A Phase 1, Multicenter Trial Evaluating the Safety, Tolerability, and Efficacy of Valemetostat (DS-3201) in Combination with Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
DAIICHI-SANKYO-DS3939-077
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2, Open-Label, Multicenter, First-in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors
ICHNOS-ISB-2001-101
Phase I
OPEN TO ACCRUAL
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma
IIT-GORE-REDIRICT
Phase II
OPEN TO ACCRUAL
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
- Anus
- Brain and Nervous System
- Breast
- Cervix
- Colon
- Esophagus
- Kidney
- Larynx
- Lip, Oral Cavity and Pharynx
- Liver
- Lung
- Other Digestive Organ
- Other Endocrine System
- Other Female Genital
- Other Male Genital
- Other Respiratory and Intrathoracic Organs
- Other Urinary
- Ovary
- Pancreas
- Prostate
- Rectum
- Small Intestine
- Soft Tissue
- Stomach
- Thyroid
- Unknown Sites
- Urinary Bladder
STEMLINE-MEN2312-01
Phase I
OPEN TO ACCRUAL
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer
TERREMOTO-TER-2013-C01
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2 Trial of TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Anus
- Breast
- Cervix
- Colon
- Corpus Uteri
- Esophagus
- Kidney
- Larynx
- Lip, Oral Cavity and Pharynx
- Liver
- Lung
- Melanoma, Skin
- Other Digestive Organ
- Other Endocrine System
- Other Female Genital
- Other Male Genital
- Other Respiratory and Intrathoracic Organs
- Other Skin
- Other Urinary
- Ovary
- Pancreas
- Prostate
- Rectum
- Small Intestine
- Soft Tissue
- Stomach
- Thyroid
- Urinary Bladder
TEVA-TV56278-ONC-10203
Phase I
OPEN TO ACCRUAL
A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Solid Tumors